Dr. Gary Buchschacher Jr.
Claim this profileGSK Investigational Site
Studies Colorectal Cancer
Studies Colon Cancer
3 reported clinical trials
11 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
HER2 positive
2Colon Cancer
dMMR positive
MSI-H positive
Stage III
Affiliated Hospitals
Clinical Trials Gary Buchschacher Jr. is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Dostarlimab
for Rectal Cancer
This trial is testing a drug called dostarlimab on patients with a specific type of rectal cancer who haven't been treated before. The goal is to see if this drug alone can treat the cancer effectively, so patients might avoid more aggressive treatments like chemotherapy, radiation, and surgery. Dostarlimab (Jemperli™) has been approved in the EU and USA for treating certain types of cancer.
Recruiting1 award Phase 2
More about Gary Buchschacher Jr.
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Gary Buchschacher Jr. has experience with
- Dostarlimab
- Tucatinib
- Trastuzumab
- Fluorouracil
- Levoleucovorin
- Leucovorin
Breakdown of trials Gary Buchschacher Jr. has run
Colorectal Cancer
Colon Cancer
Rectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary Buchschacher Jr. specialize in?
Gary Buchschacher Jr. focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Gary Buchschacher Jr. currently recruiting for clinical trials?
Yes, Gary Buchschacher Jr. is currently recruiting for 3 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Gary Buchschacher Jr. has studied deeply?
Yes, Gary Buchschacher Jr. has studied treatments such as Dostarlimab, Tucatinib, Trastuzumab.
What is the best way to schedule an appointment with Gary Buchschacher Jr.?
Apply for one of the trials that Gary Buchschacher Jr. is conducting.
What is the office address of Gary Buchschacher Jr.?
The office of Gary Buchschacher Jr. is located at: GSK Investigational Site, Los Angeles, California 90027 United States. This is the address for their practice at the GSK Investigational Site.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.